French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

NCT06147843 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital, Limoges

Phase

Not applicable

Started

2024-09-17

Last updated

2026-08-06

Condition(s) studied

Amyotrophic Lateral Sclerosis

Investigational drug(s) / intervention(s)

Blood sample

Blood sample: Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss

Study summary

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.

Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis. * Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany. * Patients who signed the informed consent form. * Adults aged \>18 years old Exclusion Criteria: * Inability to understand the requirements of the protocol. * Cognitive inability to sign and comprehend the informed consent form. * Patients who will not accept Riluzole therapy during their follow-up.

Primary outcome measure(s)

Survival — every 6 month until 18 months of follow up
Survival evaluated in month since diagnosis

Trial sites (9)

Facility	City	Region	Status
CHU de Lille	Lille	France	Recruiting
Limoges University Hospital	Limoges	France	Recruiting
Hôpital de la Timone	Marseille	France	Recruiting
Hôpital Gui Chauliac	Montpellier	France	Recruiting
CHU de Nice	Nice	France	Recruiting
Hôpital de la Pitié Salpêtrière	Paris	France	Recruiting
CHU de Tours	Tours	France	Recruiting
Klinik für Medizinische Hochschule Hannover Carl-Neuberg-Str. 1	Hanover	Allemagne	Not Yet Recruiting
Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKU	Ulm	Allemagne	Not Yet Recruiting

Other trials for the same condition

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Recruiting

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis Recruiting

FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS Recruiting

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS Active, not recruiting

Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06147843 on ClinicalTrials.gov ↗ ← All trials in Germany